UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000044256
Receipt number R000050340
Scientific Title A study on immunoglobulin behavior in desensitization therapy
Date of disclosure of the study information 2021/05/19
Last modified on 2021/05/19 14:29:39

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A study on immunoglobulin behavior in desensitization therapy

Acronym

A study on immunoglobulin behavior in desensitization therapy

Scientific Title

A study on immunoglobulin behavior in desensitization therapy

Scientific Title:Acronym

A study on immunoglobulin behavior in desensitization therapy

Region

Japan


Condition

Condition

allergic rhinitis

Classification by specialty

Oto-rhino-laryngology Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Investigate immunoglobulins

Basic objectives2

Others

Basic objectives -Others

Elucidation of the mechanism of immunity

Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Immunoglobulin levels

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

Patients who have rhinitis symptoms for 2 years or more due to cedar pollen allergy

Key exclusion criteria

Patients taking steroids

Target sample size

40


Research contact person

Name of lead principal investigator

1st name Tadao
Middle name
Last name Enomoto

Organization

non-profit organization Japan Health Promotion Support Organization

Division name

none

Zip code

640-8269

Address

68, Komatsubaratoori 3-chome, Wakayama city, Wakayama, Japan

TEL

073-432-0582

Email

t-enomoto@tempo.ocn.ne.jp


Public contact

Name of contact person

1st name Yuki
Middle name
Last name Shiraishi

Organization

EPS Holdings, Inc.

Division name

Souken Center

Zip code

162-0821

Address

9F Kagurazaka AK Building, 1-8 Tsukudo-cho, Shinjuku-ku, Tokyo, Japan

TEL

070-3023-8212

Homepage URL


Email

shiraishi094@eps.co.jp


Sponsor or person

Institute

non-profit organization Japan Health Promotion Support Organization

Institute

Department

Personal name



Funding Source

Organization

EPS holdings Inc.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Medical Station Clinic Research Ethics Committee

Address

3-12-8, Takaban, Meguro-ku, Tokyo

Tel

03-6452-2712

Email

saito876@eps.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

だけクリニック耳鼻咽喉科・アレルギー科(和歌山県)、池田耳鼻いんこう科院(和歌山県)


Other administrative information

Date of disclosure of the study information

2021 Year 05 Month 19 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2021 Year 04 Month 14 Day

Date of IRB


Anticipated trial start date

2021 Year 05 Month 01 Day

Last follow-up date

2022 Year 11 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Immunoglobulin is measured in patients with rhinitis due to Sugi pollen allergy.


Management information

Registered date

2021 Year 05 Month 19 Day

Last modified on

2021 Year 05 Month 19 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000050340


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name